Response: Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus (Diabetes Metab J 2011;35:159-65)

Soon Ae Kim; Woo Ho Shim; Eun Hae Lee; Young Mi Lee; Sun Hee Beom; Eun Sook Kim; Jeong Seon Yoo; Ji Sun Nam; Min Ho Cho; Jong Suk Park; Chul Woo Ahn; Kyung Rae Kim

doi:10.4093/dmj.2011.35.3.300

Articles

Page Path: HOME > Diabetes Metab J > Volume 35(3); 2011 > Article

Response Response: Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus (Diabetes Metab J 2011;35:159-65): Soon Ae Kim¹, Woo Ho Shim¹, Eun Hae Lee¹, Young Mi Lee¹, Sun Hee Beom¹, Eun Sook Kim¹, Jeong Seon Yoo¹, Ji Sun Nam¹, Min Ho Cho¹, Jong Suk Park^1,2, Chul Woo Ahn^1,2, Kyung Rae Kim¹; Diabetes & Metabolism Journal 2011;35(3):300-301.
DOI: https://doi.org/10.4093/dmj.2011.35.3.300
Published online: June 30, 2011

3,370 Views
27 Download
1 Crossref
3 Scopus

¹Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

²Severance Institute for Vascular and Metabolic Research, Yonsei University, Seoul, Korea.

Corresponding author: Chul Woo Ahn. Division of Endocrinology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 612 Eonju-ro, Gangnam-gu, Seoul 135-270, Korea. acw@yuhs.ac

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Full Article

Download PDF

NOTES
REFERENCES

We appreciate the comments on our study "Predictive clinical parameters for the therapeutic efficacy of sitagliptin in Korean type 2 diabetes mellitus," which was published in Diabetes & Metabolism Journal 2011;35:159-65.

Sitagliptin is an oral hypoglycemic agent with characteristics that may make it particularly useful for treating type 2 diabetes mellitus (T2DM) [1]. The drug is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4) [2], which inactivates the incretins glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. By inhibiting the activity of DPP-4, sitagliptin stabilizes the active forms of these incretins, thereby supporting glucose homeostasis through mechanisms that are not in themselves likely to trigger hypoglycemia [3]. Previous randomized placebo-controlled clinical trials have shown that sitagliptin is an effective glucose lowering agent in patients with T2DM when used as monotherapy and when given in combination with other drugs such as metformin, sulfonylurea and thiazolidinediones [4-7]. In a meta-analysis of 18 randomized controlled trials, patients were more likely to reach the HbA1c goal of <7% when treated with sitagliptin compared with placebo (POR, 3.15; 95% confidence interval [CI], 2.47 to 3.72); sitagliptin was also associated with greater decline in HbA1c from baseline compared with placebo (WMD, -0.78%; 95% CI, -0.93 to -0.63) [8]. That study reported that sitagliptin treatment lead to improvements in glycemic control in patients with T2DM, including reductions in HbA1c 0.7 to 1.2%, and 17 to 63% of patients achieved HbA1c <7% at the end of the treatment.

In our study, treatment with 100 mg sitagliptin with metformin or sulfonylurea for 24 weeks led to additional reductions of mean HbA1c to 1.23±1.15%. The likelihood of patients to reach the HbA1c goal of <7% with sitagliptin treatment was 47% at the end of 24 weeks. This glycemic lowering effect is greater than that observed in previous studies [9,10]. In addition, the HbA1c lowering effect of sitagliptin was more pronounced in non-obese patients and in patients with decreased insulin secretion compared with the non-responder group. This potent effects of sitagliptin are expected in Korean diabetic patients who have quantitative pancreatic deficiencies. Asian T2DM patients have relatively lower level of pancreatic secretory dysfunction than patients of European descent. Most studies of sitagliptin have demonstrated significant improvements in β-cell function [11,12]. Therefore, sitagliptin appears to be effective for the treatment of T2DM, and may become a first-line treatment in the future.

As Dr. Oh noted, our study has some limitations. It is retrospective, and did not control for other factors such as exercise and diet. Despite these limitations, the results of our study indicate that sitagliptin treatment greatly reduces glucose level in younger, non-obese Korean T2DM patients. Further prospective studies with larger sample sizes are needed to determine the specific effects of sitagliptin.

NOTES

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Barzilai N, Guo H, Mahoney EM, Caporossi S, Golm GT, Langdon RB, Williams-Herman D, Kaufman KD, Amatruda JM, Goldstein BJ, Steinberg H. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011;27:1049-1058. Article PubMed
2. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo [4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:141-151. Article PubMed
3. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705. Article PubMed
4. Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010;70:489-512. Article PubMed
5. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-2637. Article PubMed PDF
6. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-2643. Article PubMed PDF
7. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-1568. Article PubMed
8. Esposito K, Cozzolino D, Bellastella G, Maiorino MI, Chiodini P, Ceriello A, Giugliano D. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011;13:594-603. Article PubMed
9. Seck T, Nauck M, Sheng D, Sunga S, Davies MJ, Stein PP, Kaufman KD, Amatruda JM. Sitagliptin Study 024 Group. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010;64:562-576. Article PubMed
10. Iwamoto Y, Tajima N, Kadowaki T, Nonaka K, Taniguchi T, Nishii M, Arjona Ferreira JC, Amatruda JM. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 2010;12:613-622. Article PubMed
11. Riche DM, East HE, Riche KD. Impact of sitagliptin on markers of beta-cell function: a meta-analysis. Am J Med Sci 2009;337:321-328. PubMed
12. Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, Cobelli C, Stein PP. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 2008;10:1212-1220. Article PubMed

Figure & Data

References

Citations

Citations to this article as recorded by

Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study
Kentaro Watanabe, Susumu Yamaguchi, Yoshinori Kosakai, Tetsuya Ioji, Hisamitsu Ishihara
Clinical Drug Investigation.2023; 43(12): 927. CrossRef

PubReader

Cite

CITE: export Copy Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Response: Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus (Diabetes Metab J 2011;35:159-65)

Diabetes Metab J. 2011;35(3):300-301. Published online June 30, 2011

DOI: https://doi.org/10.4093/dmj.2011.35.3.300

XML Download